Appendix A2.
Pap smear test meta-analysis data
Study | Type* | ni11 | ni10 | ni00 | ni01 |
---|---|---|---|---|---|
Alloub et al | SC | 8 | 23 | 84 | 3 |
Alons-van Kordelaar and Boon | SC | 31 | 43 | 14 | 3 |
Anderson et al | SC | 70 | 121 | 25 | 12 |
Anderson et al | FU | 65 | 6 | 6 | 10 |
Anderson et al | FU | 20 | 19 | 4 | 3 |
Andrews et al | FU | 35 | 20 | 156 | 92 |
August | FU | 39 | 111 | 271 | 7 |
Bigrigg et al | SC | 567 | 140 | 157 | 117 |
Bolger and Lewis | SC | 26 | 12 | 18 | 37 |
Byme et al | FU | 38 | 17 | 37 | 28 |
Chomet | SC | 45 | 15 | 48 | 35 |
Engineer and Misra | SC | 71 | 10 | 306 | 87 |
Fletcher et al | FU | 4 | 36 | 5 | 0 |
Frisch et al | SC | 2 | 3 | 21 | 2 |
Giles et al | SC | 5 | 3 | 182 | 9 |
Giles et al | FU | 38 | 7 | 62 | 21 |
Gunderson et al | SC | 4 | 16 | 31 | 2 |
Haddad et al | SC | 87 | 12 | 9 | 13 |
Hellberg et al | SC | 15 | 65 | 15 | 3 |
Helmerhorst et al | FU | 41 | 61 | 29 | 1 |
Hirschowitz et al | FU | 76 | 11 | 12 | 12 |
Jones DED et al | FU | 10 | 48 | 174 | 4 |
Jones MH et al | FU | 28 | 28 | 77 | 11 |
Kashimura et al | SC | 3 | 5 | 1 | 0 |
Kealy | FU | 79 | 13 | 182 | 26 |
Koonlng-1 et al | FU | 61 | 27 | 35 | 20 |
Koonlng-2 et al | FU | 62 | 16 | 49 | 20 |
Kwikkel et al | FU | 284 | 68 | 68 | 31 |
Lozowski et al | FU | 66 | 20 | 44 | 25 |
Maggi et al | FU | 40 | 12 | 47 | 43 |
Morrison EAB et al | FU | 11 | 1 | 2 | 1 |
Morrison BW et al | SC | 23 | 10 | 44 | 50 |
Nyirjesy | SC | 65 | 42 | 13 | 13 |
Okagaki and Zelterman | SC | 1270 | 263 | 1085 | 927 |
Oyer and Hanjanl | FU | 223 | 74 | 83 | 22 |
Parker | SC | 154 | 20 | 237 | 30 |
Pearlstone et al | FU | 6 | 12 | 81 | 2 |
Ramlrez et al | SC | 7 | 3 | 4 | 4 |
Reld et al | SC | 12 | 11 | 60 | 5 |
Robertson et al | FU | 348 | 212 | 103 | 41 |
Schauberger et al | SC | 8 | 11 | 34 | 4 |
Shaw | FU | 12 | 6 | 0 | 2 |
Singh et al | FU | 95 | 2 | 1 | 9 |
Skehan et al | FU | 40 | 20 | 19 | 18 |
Smith et al | FU | 71 | 20 | 18 | 13 |
Soost et al | SC | 1205 | 454 | 241 | 186 |
Soutter-1 et al | SC | 5 | 52 | 27 | 20 |
Soutter-2 et al | SC | 35 | 12 | 12 | 9 |
Spitzer et al | FU | 10 | 5 | 32 | 31 |
Stafi | SC | 3 | 3 | 15 | 5 |
Syrjanen et al | FU | 118 | 44 | 183 | 40 |
Szarewski | SC | 13 | 82 | 17 | 3 |
Tait et al | SC | 38 | 13 | 62 | 14 |
Tawa et al | SC | 14 | 67 | 291 | 25 |
Tay et al | FU | 12 | 6 | 12 | 14 |
Upadhyay et al | SC | 238 | 2 | 16 | 52 |
Walker et al | FU | 111 | 20 | 39 | 44 |
Wetrich | FU | 491 | 250 | 702 | 164 |
Wheelock and Kamlnlski | FU | 49 | 39 | 31 | 16 |
type of the study denotes the usage of the test clinically, SC as screening and FU as follow up.